Kisspeptin-10 is a short piece of a natural human hormone that sits at the very top of the chain of command for reproduction. If the reproductive system were a company, kisspeptin would be the executive who sends the first memo of the day — the signal that sets everything below it in motion. That upstream position is exactly why it interests fertility researchers: it does not bypass the body's own machinery, it switches it on.
In plain terms: the master "start" button for the reproductive hormones, tested in real people.
What it is
Kisspeptin is a natural signalling protein made in the brain, produced from a gene called KISS1. The full molecule circulates as a 54-amino-acid form (kisspeptin-54), but the business end — the shortest fragment that keeps the full activity — is the last 10 amino acids, which is kisspeptin-104. So kisspeptin-10 is a trimmed-down but fully active version of the natural hormone.
It acts on a receptor called KISS1R (older name GPR54), found on the neurons in the hypothalamus that produce GnRH4.
How it works — one step up the ladder
The reproductive hormone system is a relay. It helps to see the whole chain:
- Kisspeptin switches on the neurons that make GnRH.
- GnRH (gonadotropin-releasing hormone) travels to the pituitary and tells it to release two gonadotropins.
- LH and FSH (luteinizing and follicle-stimulating hormone) travel in the blood to the gonads.
- The gonads respond: LH drives the testes to make testosterone or triggers ovulation in the ovaries; FSH supports sperm and egg development.
Kisspeptin-10 acts at the top of that relay — above GnRH2. This is the key difference from GnRH-based peptides like gonadorelin, which act one rung lower, directly on the pituitary. By acting on the GnRH neurons themselves, kisspeptin recruits the body's own pulse generator rather than replacing it.
In plain terms: gonadorelin pokes the pituitary directly; kisspeptin pokes the brain cell that normally pokes the pituitary.
Pharmacokinetics — fast on, fast off
Kisspeptin-10 is a small peptide and it acts quickly and briefly. In human studies an intravenous bolus produced a rapid rise in LH within minutes, and the molecule itself clears from the blood on a timescale of minutes, not hours2. Because of that short action, researchers have studied it both as single injections and as continuous infusions to sustain an effect3.
What the studies actually found
Kisspeptin has a real body of human data — much of it from the group led by Waljit Dhillo at Imperial College London. Note the model in each row:
| Study | Model / level | Key result | Year |
|---|---|---|---|
| Dhillo et al.1 | Human men (kisspeptin-54) | Infusion raised LH, FSH and testosterone versus saline — first proof it drives the human axis | 2005 |
| George et al.2 | Human men (kisspeptin-10) | Bolus raised LH dose-dependently (peak at ~1 microgram/kg); infusion increased LH pulse frequency | 2011 |
| Jayasena et al.3 | Human men and women (kisspeptin-10) | Stimulated gonadotropins in men and preovulatory women, but not in early follicular-phase women | 2011 |
Two findings are worth drawing out. First, kisspeptin-10 does not just raise hormone levels — it increases the pulse frequency of the axis2. That matters because the reproductive system speaks in pulses; the rhythm carries the message, and a peptide that changes the rhythm is acting on the system the way the body naturally does. Second, its effect is sex- and cycle-dependent: the same dose that worked in men did little in women during the early part of the menstrual cycle3. Researchers call this sexual dimorphism, and it is a reminder that the reproductive axis is not a simple on/off switch.
The fertility and libido angle
Because kisspeptin sits at the top of the axis, it has become a research tool for exploring fertility. It has been tested as an alternative way to trigger egg maturation and to investigate disorders where the axis is switched off. Some kisspeptin research has also examined links to sexual and emotional processing in the brain. All of this is research — kisspeptin is not an approved fertility or libido treatment, and this page describes what studies looked at, not how anyone should use it.
Honest limitations
Kisspeptin-10 is on firmer human ground than many research peptides — genuine controlled human studies exist123. But keep the limits in view. These studies are mostly small and short, designed to understand physiology, not to prove a treatment. The effect is brief, and the axis can desensitise to continuous high exposure, the same way the GnRH system does. And it remains a research compound, not an approved medicine. This is an educational overview, not medical advice, and it takes no position on sourcing.
Latest research
- The foundational human proof came in 2005 (kisspeptin-54)1 and was extended to kisspeptin-10 in 2011, showing dose-dependent LH release and faster pulses in men2.
- The sex-difference finding from 2011 remains important: kisspeptin's effect depends on sex and cycle phase, which shapes how it could ever be used in reproductive medicine3.
- Kisspeptin fertility research is active, with ongoing trials probing its use to trigger egg maturation and to study reproductive and psychosexual disorders. We update this section as results report.
The short version
Kisspeptin-10 is a short, fully active fragment of a natural human hormone that switches on the reproductive axis at its source — one step above GnRH. Human studies from the Dhillo group show it raises LH and testosterone in men and increases the pulse frequency the system runs on, with effects that depend on sex and cycle phase. It has real human data but remains a research peptide, not a medicine. Educational overview only. See also gonadorelin and hCG.